The Legacy of Scientific Racism
By Prabir Purkayastha,
LA Progressive
| 08. 10. 2022
In July, the world celebrated 200 years since the birth of Gregor Mendel, who is widely accepted as the “father of modern genetics” for his discovery of the laws of inheritance. His experiments with peas, published in 1866 under the title “Experiments in Plant Hybridization,” identified dominant and recessive traits and how recessive traits would reappear in future generations and in what proportion. His work would largely remain unacknowledged and ignored until three other biologists replicated his work in 1900.
While Mendel’s work is central to modern genetics, and his use of experimental methods and observation is a model for science, it also set off the dark side with which genetics has been inextricably linked: eugenics and racism. But eugenics was much more than race “science.” It was also used to argue the superiority of the elite and dominant races, and in countries like India, it was used as a “scientific” justification for the caste system as well.
People who believe that eugenics was a temporary aberration in science and that it died with Nazi Germany would be...
Related Articles
By Timnit Gebru and Émile P. Torres, First Monday | 04.14.2024
The stated goal of many organizations in the field of artificial intelligence (AI) is to develop artificial general intelligence (AGI), an imagined system with more intelligence than anything we have ever seen. Without seriously questioning whether such a system can...
By Harold Brubaker, The Philadelphia Inquirer | 04.04.2024
Acompany started by University of Pennsylvania scientist Jim Wilson has received FDA approval to test a form of gene editing in infants for the first time in the United States, the company said Thursday.
The Plymouth Meeting company, iECURE, is...
By Jason Kehe, Wired | 04.11.2024
God help the babies! Or, absent God, a fertility startup called Orchid. It offers prospective parents a fantastical choice: Have a regular baby or have an Orchid baby. A regular baby might grow up and get cancer. Or be born...
By Nick Paul Taylor, BioSpace | 03.14.2024
A U.K. watchdog balked at the cost-effectiveness of Vertex Pharmaceuticals’ CRISPR-based sickle cell disease therapy Thursday, recommending against funding the treatment unless uncertainties can be cleared up satisfactorily.
The U.K. became the first country to authorize Vertex’s Casgevy (exagamglogene...